JP2022533578A5 - - Google Patents

Info

Publication number
JP2022533578A5
JP2022533578A5 JP2021566974A JP2021566974A JP2022533578A5 JP 2022533578 A5 JP2022533578 A5 JP 2022533578A5 JP 2021566974 A JP2021566974 A JP 2021566974A JP 2021566974 A JP2021566974 A JP 2021566974A JP 2022533578 A5 JP2022533578 A5 JP 2022533578A5
Authority
JP
Japan
Prior art keywords
cancer
patient
tumor
treatment agent
antibody molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021566974A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533578A (ja
Filing date
Publication date
Priority claimed from GBGB1906807.1A external-priority patent/GB201906807D0/en
Priority claimed from GB201914040A external-priority patent/GB201914040D0/en
Priority claimed from GBGB2000318.2A external-priority patent/GB202000318D0/en
Application filed filed Critical
Priority claimed from PCT/EP2020/063529 external-priority patent/WO2020229626A1/en
Publication of JP2022533578A publication Critical patent/JP2022533578A/ja
Publication of JP2022533578A5 publication Critical patent/JP2022533578A5/ja
Pending legal-status Critical Current

Links

JP2021566974A 2019-05-14 2020-05-14 Lag-3/pd-l1二重特異性抗体の投与のための投与計画 Pending JP2022533578A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1906807.1A GB201906807D0 (en) 2019-05-14 2019-05-14 Dosages regimes for the administration of lag-3/pd-l1 bispectic antibody
GB1906807.1 2019-05-14
GB201914040A GB201914040D0 (en) 2019-09-30 2019-09-30 Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody
GB1914040.9 2019-09-30
GBGB2000318.2A GB202000318D0 (en) 2020-01-09 2020-01-09 Dosage regimes for the administration of LAG-3/PD-L1 bispecific antibody
GB2000318.2 2020-01-09
PCT/EP2020/063529 WO2020229626A1 (en) 2019-05-14 2020-05-14 Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody

Publications (2)

Publication Number Publication Date
JP2022533578A JP2022533578A (ja) 2022-07-25
JP2022533578A5 true JP2022533578A5 (cg-RX-API-DMAC7.html) 2023-05-17

Family

ID=70775359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021566974A Pending JP2022533578A (ja) 2019-05-14 2020-05-14 Lag-3/pd-l1二重特異性抗体の投与のための投与計画

Country Status (12)

Country Link
US (1) US20220275092A1 (cg-RX-API-DMAC7.html)
EP (1) EP3969477A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022533578A (cg-RX-API-DMAC7.html)
KR (1) KR20220008316A (cg-RX-API-DMAC7.html)
CN (1) CN114206939A (cg-RX-API-DMAC7.html)
AU (1) AU2020275209A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022831A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139003A1 (cg-RX-API-DMAC7.html)
IL (1) IL287979A (cg-RX-API-DMAC7.html)
MX (1) MX2021013943A (cg-RX-API-DMAC7.html)
SG (1) SG11202112136RA (cg-RX-API-DMAC7.html)
WO (1) WO2020229626A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
AU2019301206B2 (en) 2018-07-12 2025-10-30 Invox Pharma Limited Antibody molecules that bind CD137 and OX40
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
BR112021000394A2 (pt) 2018-07-12 2021-04-06 F-Star Beta Limited Moléculas de anticorpo que se ligam a pd-l1 e cd137
CN118165116A (zh) * 2021-03-31 2024-06-11 美勒斯公司 新型多特异性抗体
US20240101718A1 (en) * 2022-09-28 2024-03-28 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof
GB202304278D0 (en) 2023-03-23 2023-05-10 F Star Therapeutics Ltd Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7085709B2 (ja) 2016-06-20 2022-06-17 エフ-スター セラピューティクス リミテッド Pd-l1及びlag-3に結合する結合分子
JP2020522495A (ja) * 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 抗lag−3抗体、pd−1経路阻害剤および免疫療法剤の組み合わせを含む組成物
WO2018222718A1 (en) * 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors

Similar Documents

Publication Publication Date Title
Dillon et al. PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours
Boku et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
JP2019521087A5 (cg-RX-API-DMAC7.html)
CN104114168A (zh) 治疗增殖性疾病的联合疗法(威罗菲尼和mdm2抑制剂)
JP7750884B2 (ja) HIF-2α阻害剤とレンバチニブの組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法
JP2023542093A (ja) 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用
CN115429883A (zh) 用于联合治疗的抗肿瘤药物组合物
Von Hoff et al. New drugs for patients with pancreatic cancer
AU2015242786B2 (en) Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer
CN118846070A (zh) 一种用于治疗kras突变肿瘤的药物组合物及应用
JP2024515100A5 (cg-RX-API-DMAC7.html)
JP7168575B2 (ja) トリフルリジン/チピラシル塩酸塩、抗腫瘍白金錯体、及び免疫チェックポイント調節剤の新規組み合わせ物
RU2021135011A (ru) Режимы дозирования при введении биспецифичного антитела против lag -3/pd-l1
Cohen et al. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors
US11911374B2 (en) Methods and uses for treating cancer
US20250049802A1 (en) Combination therapies and uses for treating cancer
WO2026103823A1 (zh) Ras抑制剂和egfr抑制剂的组合及其用途
CN113573707A (zh) 用于治疗癌症的组合产品
Rosen et al. 400 POSTER Early evidence of tolerability and clinical activity from a phase 1 study of TRC105 (anti-CD105 antibody) in patients with advanced refractory cancer
WO2026103822A1 (zh) Ras抑制剂和pd-1或pd-l1抑制剂的组合及其用途
Yamazaki et al. 217TiP Dose-finding phase Ib study of FOLFOXIRI plus ramucirumabas first-line therapy for patients with metastatic colorectal cancer
HK40015395A (en) Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator
Calvo et al. 586 Dose Determination of LY2603618 Administered in Combination with Pemetrexed and Cisplatin in Patients with Advanced Cancer
Leong et al. 402 POSTER A phase I study of gemcitabine, capecitabine and vandetanib in patients with advanced solid tumors with an expanded cohort in biliary and pancreatic malignancies
Wakelee et al. 401 POSTER A phase I study of enzastaurin (ENZ), an oral PKC inhibitor, in combination with erlotinib (ERL) administered orally daily to patients with advanced solid malignancies